Get the Stockscreener App
4.71
5.04%
-0.25
After Hours:
4.80
0.09
+1.91%
Atara Biotherapeutics Inc stock is traded at $4.71, with a volume of 66,242.
It is down -5.04% in the last 24 hours and down -10.46% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
See More
Previous Close:
$4.96
Open:
$4.88
24h Volume:
66,242
Relative Volume:
0.18
Market Cap:
$38.52M
Revenue:
$120.77M
Net Income/Loss:
$32.69M
P/E Ratio:
1.616
EPS:
2.9146
Net Cash Flow:
$-50.94M
1W Performance:
-8.01%
1M Performance:
-10.46%
6M Performance:
-65.72%
1Y Performance:
-28.85%
1-Day Range:
$4.70
$5.0691
1-Week Range:
$4.70
$5.35
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.71 | 40.56M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
[EFFECT] Atara Biotherapeutics, Inc. SEC Filing - Stock Titan
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Caledonian Record
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Atara Biotherapeutics (ATRA) registers 400,000 shares for resale by HCR - Stock Titan
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
Drug Co. Atara Hit With Investor Suit Over FDA Denial - Law360
INVESTOR ALERT: Securities Class Action Filed Against Atara Biotherapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - The AI Journal
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - The Daily Tribune News
ATRA Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Atara Biotherapeutics, Inc. - PR Newswire
Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit - The AI Journal
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of ... - Bluefield Daily Telegraph
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara - GlobeNewswire
Panacea entities boost Atara (ATRA) stake via 259,163-share warrant exercise - Stock Titan
What are analysts price targets for Atara Biotherapeutics Inc2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Form S-3 Atara Biotherapeutics Inc For: 18 March By Investing.com - Investing.com
[S-3] Atara Biotherapeutics, Inc. Shelf Registration Statement | ATRA SEC FilingForm S-3 - Stock Titan
Market Recap: Will Atara Biotherapeutics Inc benefit from AI trendsEarnings Trend Report & Weekly Momentum Stock Picks - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application - Investing.com Nigeria
Atara Biotherapeutics, Inc. 2025 Annual Report: Strategic Alternatives, Business Overview, and Risk Factors - Minichart
Form 424B5 Atara Biotherapeutics Inc For: 16 March By Investing.com - Investing.com Australia
Atara Biotherapeutics: Q4 Loss & Annual Profit 2025 Financial ResultsNews and Statistics - IndexBox
Atara Biotherapeutics: Q4 Earnings Snapshot - Barchart
Atara Biotherapeutics (NASDAQ: ATRA) registers $11.1M ATM offering via TD Cowen - Stock Titan
Atara Biotherapeutics (ATRA) bets on tab-cel as layoffs, FDA pushback mount - Stock Titan
Atara (NASDAQ: ATRA) turns 2025 profit and targets cash runway into 2026 - Stock Titan
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - The Joplin Globe
Atara Biotherapeutics: Fourth Quarter Earnings Overview - Bitget
Atara Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” - The Cancer Letter
Weekly Trades: Will Atara Biotherapeutics Inc benefit from AI trendsQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel - marketscreener.com
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus
Atara Plans FDA Type A Meeting on EBVALLO - TipRanks
Atara Biotherapeutics schedules FDA Type A meeting on EBVALLO BLA complete response - TradingView
FDA to hold Type A meeting on Atara Biotherapeutics (ATRA) EBVALLO tab-cel BLA - Stock Titan
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - FinancialContent
Atara (ATRA) CEO granted 81,100 RSUs, now holds 143,078 shares - Stock Titan
Atara Biotherapeutics (ATRA) awards 20,300 RSUs to Chief Accounting Officer - Stock Titan
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus - TechStock²
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aug Closing: Can Atara Biotherapeutics Inc sustain earnings growth2026 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Chart Watch: Is Atara Biotherapeutics Inc being accumulated by smart moneyJobs Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):